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ABSTRACT : In HMG-HCG therapy, the FSH level in serum increases gradually by 
administering HMG every day. Such an unphysiological phenomenon develops and 
matures many follicles simultaneously, leading to OHSS and multiple pregnancy. 
Contrarily in the every-other-day administration, the FSH level in serum remains almost 
unchanged or increases only slightly and less mature follicles are developed. The risk 
of causing OHSS and multiple pregnancy is lowered in this way. The every-other-day 
administration is therfore considered to be a valuable method causing less side effects. 
The demerit of lower ovulation rate in the every-other-day administration could be 
amended by some methodological improvement. It is concluded that this a promising 
therapy.
       INTRODUCTION 
 Serious side effects of HMG-HCG therapy are 
multiple pregnancy and ovarian hyperstimula-
tion syndrome (DHSS). At present it is difficult 
to prevent multiple pregnancy. While a rapid 
measurements' of blood estrogen and ultrasonic 
tomography" are reported to be useful for 
prevention of OHSS. In the present study an 
equal dose of HMG was administered every 
other day for comparison with the every-day 
administration in terms of the rate of ovulation, 
that of pregnancy and the incidence of OHSS.
   MATERIALS AND METHODS 
1. Eleven anovulatory women received 781U, 
1501U or 2251U of HMG per day every day or 
every other day in a total of 10 times, LH and 
FSH levels in serum were measured by radioim-
munoassay. 
2. This trial was carried out in 64 anovulatory 
women (253 cycles) in total: 2 cases of
anovulation (5 cycles), 17 cases of 1st grade 
amenorrhea (64 cycles), 45 cases of 2 nd grade 
amenorrhea (184 cycles). Humegon' (HMG) was 
adiministered ten times at 751U, 1501U or 2251U 
per day every day into 42 cases (198 cycles) and 
every other day into 22 other cases (55 cycles), 
and subsequently HCG was adminstered once 
to three times every other day at 5,000IU to 
10,0001U per day, that is 30,0001U or less in total. 
 Administration of HMG was planned to be 
started on the fifth day of hormone withdrawal 
bleeding in principle, but in some cases of 
every-other-day administration the onset was on 
its second day. At the time when the cervical 
mucus became more than 0.3 ml during HMG 
therapy, HCG was administered. In both me-
thods of the every-day and every-other-day 
administration, the ovulation rate, incidence of 
OHSS and pregnancy rate were examined. In 
18 of the every-day administration cases, every-
other-day administration was also tried with the 
same dosage after an interval of several months 
and the ovulation rate, incidence of OHSS and 
the days till the ovulation (the period from the
onset day of hormone withdrawal bleeding to 
the final day of the hypothermic phase of the 
basal bldy temperature) were compared between 
the 2 methods. All the cases where the ovary 
measured 5cm or more in diameter by ultrasonic 
tomography using a Toshiba SAL-30A Electric 
Scan, were decided to have OHSS, regardless 
of the presence of subjective or objective symp-
toms, according to the criteria of Jewelewicz3'. 
3. Estimation of the nuumber of follicles 
 The total number of follicles per treatment 
cycle and that of the follicles of 15mm or more 
in diameter were estimated through delineation 
by ultrasonic tomography in 42 cases (78 cycles) 
administered every day and in 22 cases (39 
cycles) administered every other day.
          RESULTS 
1. Changes in serum LH and FSH levels during 
HMG administration 
1) Changes in serum LH level (Fig. 1) 
   No significant difference was observed bet-
 ween the 2 methods of every-day and every-
 other-day administration. Generally, in both 
 methods, serum LH level remained constant 
 although it slightly increased in a few cases. 
2) Changes in serum FSH level (Fig. 2)
 A gradual increase of serum FSH level was 
observed in cases administered every day and 
the degree of increase was more remarkable 
in 225 IU cases than in 1501U cases. Cases 
administered every other day with 2251U 
showed a tendency of gradual increase in 
much less degree compared to those ad-
ministered every day with the same dose. In 
cases administered every other day with 751U 
or 1501U per day, an undulatory change was 
seen in the serum FSH level, indicating a 
tendency of little or no increase.
2. Ovulation rate, incidence of OHSS and pre-
gnacy rate (Table 1) 
 The ovulation rate and incidence of OHSS by 
cycle were 69.2% and 22.2% respectively in the 
every-day administration, and 38.2% and 3.6% 
respectively in the every-other-day administra-
tion. It means that the ovulation rate was hig-
her in the former method (p<0.001) while the 
incidence of OHSS was definitely lower in the 
latter (p<0.005). As to the pregnancy rate, the 
every-day administration showed a higher rate 
(52%) compared with the every-other-day ad-
ministration (10%) (p<0.1). Multiple pregnancy 
was observed only in 3 cases (23.1%) adminis-
tered every day and all were twins. In the 18
Fig. 1. Serum LH level during HMG treatment
Fig. 2. Serum FSH level during HMG treatment
   Table 1. The Results of HMG administration with uniform daily and every-other daily dose 
                  ovulation ovarian hypersti- Incidence of Incidence of
                                 mulation syndrome pregnancies multiple pregnancies 
            A B A B A B A B 
            (cycle) (cycle) (cycle) (cycle) (cycle) (cycle) (cycle) (cycle) 
Anovulatory 2/3 1/2 0/3 0/2 1/1 0/1 0/1 
  cycle (66.7%) (50.0%) (0%) (0%) (100%) (0%) (0%) 
 1st grade 35/45 8/19 15/45 2/19 1/7 1/3 0/1 0/1 
amenorrhea (77.8%) (42.1%) (33.3%) (10.5%) (14.3%) (33.3%) (0%) (0%) 
2nd grade 100/150 12/34 29/150 0/34 11/17 0/6 3/11 
amenorrhea (66.7%) (35.3%) (19.3%) (0%) (64.7%) (0%) (27.3%) 
  Total 137/198° 21/55° 44/198°° 2/55°° 13/25"°Y 1/10*** 3/13 0/1            (69
.2%) (38.2%) (22.2%) (3.6%) (52.0%) (10.0%) (23.1%) (0%) 
                                                        *P<0 .001, **P<0.005, .,<** P<0.1 
                                                      A : every-day administration 
                                                      B : every-other-day administration
cases administered every day, the every-other-
day administration was done several months 
later and the ovulation rate, incidence of OHSS 
and the days till the ovulation were examined 
in the respective administration methods (Table 
2). The ovulation rate per treatment cycle was 
70.1% in cases administered every day and 43.6% 
in those administered every-other-day, showing
a significant difference between them(p<0.01). 
The incidence of OHSS was 27.8% in the every-
day administration and 2.6% in the every-other-
day administration with a significant difference 
between them (p<0.005). The period till the 
ovulation was 15.3±3.4 days in cases admin-
istered every day and 24.0±5.2 day in those 
administered every other day. The period till
Table 2. The Results of HMG administration on the same case with uniform daily and every-other daily 
         dose 
                          ovulation ovarian hyperstimu-                                               l
ation syndrome period till ovulation 
                       case cycle case cycle 
    every-day 18/18* 68/97" 14/18"' '` 27/97'°15
.3±3.4 (69cycle) 
  administration (100%) (70.1%) (77.8%) (27.8%) 
  every-other-day 11/18: 17/39 1/39""""" 24.0±5.2 (9cycle) 
  administration (61.1%) (43.6%) (5.6%) (2.6%) 17.9±3.1 (9cycle) 
                                                P<0.025, P<0.01, P<0.001, P<0.005
Table 3 Correlation between regimen of HMG administration and ovarian hyperstimulation syndrome 
      (OHSS) 
  case diagnosis regimen of HCG dose ovulation OHSS                          HMG 
administration 
     hypothalamic 1501U/day for 10 days (A) 5,000/day for 1 day + + 
  M. N. amenorrhea 1501U/day for 10 days (A) 5,000/day for 5 days + + 
          (1st grade) 1501U/day for 10 days (B) 5,000/day for 5 days + -
         hypothalamic 2251U/day for 7 days (A) 5,000/day for 3 days + +
  R. 0. amenorrhea 2251U/day for 7 days (B) 5,000/day for 3 days + -
          (2nd grade) 2251U/ /day for 7 days (B) 5,000/day for 3 days + -
                     1501U/day for 10 days (A) 5,000/day for 2 days + -
                     1501U/day for 10 days (A) 5,000/day for 3 days + -
           pituitary 1501U/day for 10 days (A) 5,000/day for 3 days + +
  T. S. amenorrhea 1501U/day for 10 days (A) 5,000/day for 2 days + +                      
ay for 10 days (A) 5,000/day for 3 days + + 
         (2nd grade) 1501U/day for 10 days (B) 5,000/day for 5 days + -
                      1501U/day for 10 days (B) 5,000/day for 3 days - -
                      150IU/day for 10 days (B) 5,000/day for 3 days - -
                     1501U/day for 10 days (A) 5,000/day for 3 days + -h
ypothalamic 1501U/day for 10 days (A) 5
,000/day for 3 days + -
  M. N. amenorrhea 150IU/day for 10 days (A) 5,000/day for 3 days + + 
         (2nd grade) 1501U/day for 10 days (B) 5,000/day for 3 days + -              
ay for 10 days (B) 5,000/day for 3 days + -
                                                       A : every-day administration 
                                                          B : every-other-day administration
     Table 4. Number of follicles due to HMG-HCG Treatment 
                     No. of follicles No. of follicles R
egimen over 15mm in diameter
-
   Every-day 5
.2±3.7 (78cycles)' 2.2±1.6 (78cycles) "* 
 administration 
 Every-other-day 3
.7±2.4 (39cycles)* 1.2±1.0 (39cycles)'k:k 
 administration 
                                            P<0.05, * P<0.001
the ovulation in the every-other-day administra-
tion was shortend to 17.9±3.1 days when the 
administration of HMG was started on the se-
cond day of hormone withdrawal bleeding.
Seeking the relation between the dosage of HCG 
and the incidence of OHSS, the dosage of HCG, 
ovulation and incidence of OHSS were examined 
in 4 cases where the dosage per day of HMG
and the total dose were equal (Table 3). As a 
result, the occurrence of OHSS was observed 
only in cases treated every day and it showed 
a tendency of repetition. There was found no 
definite difference in the dosage of HCG between 
cases with and without OHSS. 
3. The number of follicles (Table 4) 
 The number of follicles observed in cases with 
every-day administration and those with every-
other-day administration was 5.2±3.7 and 3.7--1-
2.4, respectively, showing a significant difference 
between them (p <0.05). The number of follicles 
of 15mm or more in diameter was significantly 
increased in cases administered every day (2.2--4-
1.6) than in those administered every other day 
(1.2±1.0) (p<0.001).
         DISCUSSION 
 Yen et al.'' '' reported that the disapperance 
curve of serum FSH could be divided into two 
parts ; the early portion of fast process (initial 
component) and the subsequent later portion of 
slower process (second component) and its 
half-life was 3.9 hours in the early portion and 
70.4 hours in the latter. The half-life of LH was 
21 minutes and 3.9 hours, respectively. FSH has 
a much longer half-life than LH and this means 
that when HMG is administered, FSH in serum 
maintains a high level for a longer time than 
LH. It is predicted, therefore, that FSH and LH 
(especially FSH) accumulate gradually by ad-
ministering HMG every day. As a matter of 
fact, FSH in serum clearly increased gradually 
by administering HMG every day. Above all, 
in cases administered with 2251U per day, the 
increasing curve was very sharp (Table 2). 
This gradual increase of FSH level is. an un-
physiological phenomenon, being not seen in the 
natural ovulatory cycle, and supposedly causes 
OHSS by developing and maturing a number 
of follicles simultaneously. On the other hand, 
serum FSH in cases treated with HMG every 
other day remained at the same level and such 
a remarkably rapid increase seen in cases 
administered every day was not observed even 
when the dosage was as large as 2251U per day 
(Fig 1). This fact suggests a possibility that 
administering HMG every other day may reduce 
the incidence of OHSS. Hereupon, the ovula-
tion rate and the incidence of OHSS were 
investigated in both administration methods. 
As a result, the incidence of OHSS by the 
every-other-day administration was definitely 
lower than by the everyday administration (p< 
0.005). Considering the individual difference, 
both administration methods were tried in the 
same cases, where similar results were obtain-
ed. The incidence of OHSS was clearly lower 
in the every-other-day administration (p<0.001). 
The incidence of OHSS per treatment cycle in 
the every-day administration in the present 
study (22.2%) was much higher than that of a 
nation-wide survey in Japan (5.3%), where the 
ovary larger than a goose egg size was judged 
as OHSS. The reasons why the rate was so 
high in the present study are at first that the 
subjects were not only cases not responding to 
clomiphene and secondly that the lowest limit 
of the ovarian diameter for OHSS was set to 
be 5cm. Even though no selection was made 
on cases and the criteria for OHSS was severe 
in this way, the incidence was only 3.6% in cases 
administered every-other-day. This fact means 
that this administration method is excellent 
from the viewpoint of preventing the occurrence 
of OHSS. The mode of administration and 
dosage of HCG could also be the cause of OHSS 
in the HMG-HCG therapy. Therefore, the rela-
tion among the dosage of HCG and the in-
cidence of HCG and the incidence of OHSS was 
examined in 4 cases where the dosage and 
administration method of HCG were identical 
to one another among cases treated by both 
administration methods. No specific relation 
ship has been observed in this respect, sug-
gesting that the administration method of HMG 
rather than the dosage of HCG affects the 
occurrence of OHSS more closely. From what 
has been mentioned above, it is concluded that 
the every-other-day administration of HMG is 
a very useful method with less incidence of 
OHSS. On the other hand, it has a demerit of 
low ovulation and pregnancy rate. However, the 
ovulation rate gets higher by increasing the 
dosage of HMG per day in the every-other-day 
administration, i. e., increasing from 751U per 
day to 1501U or 2251U. In the every-other-day 
administration, a tendency of delayed ovulation 
was observed, supposedly lowering the preg-
nancy rate. Regarding this point, the period till 
the ovulation may approach that in the every-
day administration method by starting the dose 
in an early stage such as on the 2nd day of 
hormone withdrawal bleeding. 
 Another side effect of HMG-HCG therapy is 
multiple pregnancy which is due to multiple 
ovulation. For its prevention it is necessary to 
reduce the development of mature follicles as 
much as possible. The number of ovulatable 
follicles of 15mm or more in diameter was def-
initely smaller in the every-other-day adminis-
tration than in the every-day administration (p< 
0.001). This means that the possibility of mul-
tiple pregnancy is lower in the every-other-day 
administration method. Considering the serious 
influences of multiple pregnancy on mothers 
and fetuses, the every-other-day administration 
could be the first choice in spite of its lower 
ovulation rate.
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